Evidence map›Paper›PMID 25857301›Full record

ArticleOncotarget2015

Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles.

Valentina R Minciacchi, Sungyong You, Cristiana Spinelli, Samantha Morley, Mandana Zandian, Paul-Joseph Aspuria, Lorenzo Cavallini, Chiara Ciardiello, Mariana Reis Sobreiro, Matteo Morello and 11 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 253 papers.

0numbers the graph read from it
0cells of the map it votes in
253citing papers in PubMed
13.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

253 citing papers in PubMed, 387 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Does extracellular vesicle specificity truly exist?Cell communication and signaling : CCS · 2026
    Review
  20. Review

193 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 5 countries.

Valentina R MinciacchiDivision of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Sungyong YouDivision of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cristiana SpinelliDivision of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Samantha MorleyThe Urological Diseases Research Center, Boston Children's Hospital, Boston, MA, USA.
Mandana ZandianDivision of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Paul-Joseph AspuriaWomen's Cancer Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Lorenzo CavalliniDivision of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Chiara CiardielloDivision of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Mariana Reis SobreiroDivision of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Matteo MorelloDivision of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Geetanjali KharmateVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, BC, Canada.
Su Chul JangDepartment of Life Sciences, Pohang University of Science and Technology, Pohang, Republic of Korea.
Dae-Kyum KimDepartment of Life Sciences, Pohang University of Science and Technology, Pohang, Republic of Korea.
Elham Hosseini-BeheshtiVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, BC, Canada.
Emma Tomlinson GunsVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, BC, Canada.
Martin GleaveVancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, BC, Canada.
Yong Song GhoDepartment of Life Sciences, Pohang University of Science and Technology, Pohang, Republic of Korea.
Suresh MathivananDepartment of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Australia.
Wei YangDivision of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Michael R FreemanDivision of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Dolores Di VizioDivision of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Cedars-Sinai Medical Center · USUniversity of British Columbia · CAPohang University of Science and Technology · KRHarvard University · USIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · ITLa Trobe University · AUUniversity of Florence · IT

Funding

UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
Prostate Cancer Bone Metastasis: Biology and TargetingP01CA098912 · NCI · EMORY UNIVERSITY · PI ZAYZAFOON, MAJD · 2003 to 2019
$24.0M
HEPARIN-BINDING EGF-LIKE FACTORS IN PROSTATE GROWTHR37DK047556 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI FREEMAN, MICHAEL R · 2000 to 2009
$3.0M
Cholesterol and Prostate HealthR01DK087806 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI FREEMAN, MICHAEL R · 2011 to 2015
$1.9M
Amoeboid Membrane Dynamics in Prostate CancerR01CA143777 · NCI · CEDARS-SINAI MEDICAL CENTER · PI FREEMAN, MICHAEL R · 2010 to 2014
$1.7M
Membrane Microdomains in Prostate CancerR01CA112303 · NCI · CHILDREN'S HOSPITAL BOSTON · PI FREEMAN, MICHAEL R · 2005 to 2009
$1.4M
Fatty Acid Synthase, Caveolin-1 and Membrane Microdomains in Prostate CancerR00CA131472 · NCI · CEDARS-SINAI MEDICAL CENTER · PI DI VIZIO, DOLORES · 2010 to 2012
$722k
NCI NIH HHS CA112303NCI NIH HHS NCI NIH R00 CA131472NCI NIH HHS P01 CA098912NCI NIH HHS P50 CA092131NCI NIH HHS R00 CA131472NCI NIH HHS R01 CA112303NCI NIH HHS R01 CA143777NIDDK NIH HHS R01 DK087806NIDDK NIH HHS R37 DK047556NIDDK NIH HHS R37 DK47556
6 · The paper itself

Abstract

Large oncosomes (LO) are atypically large (1-10 µm diameter) cancer-derived extracellular vesicles (EVs), originating from the shedding of membrane blebs and associated with advanced disease. We report that 25% of the proteins, identified by a quantitative proteomics analysis, are differentially represented in large and nano-sized EVs from prostate cancer cells. Proteins enriched in large EVs included enzymes involved in glucose, glutamine and amino acid metabolism, all metabolic processes relevant to cancer. Glutamine metabolism was altered in cancer cells exposed to large EVs, an effect that was not observed upon treatment with exosomes. Large EVs exhibited discrete buoyant densities in iodixanol (OptiPrep(TM)) gradients. Fluorescent microscopy of large EVs revealed an appearance consistent with LO morphology, indicating that these structures can be categorized as LO. Among the proteins enriched in LO, cytokeratin 18 (CK18) was one of the most abundant (within the top 5th percentile) and was used to develop an assay to detect LO in the circulation and tissues of mice and patients with prostate cancer. These observations indicate that LO represent a discrete EV type that may play a distinct role in tumor progression and that may be a source of cancer-specific markers.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsBiomarkers, TumorCell-Derived MicroparticlesCell Line, TumorCentrifugationChromatography, High Pressure LiquidChromatography, Reverse-PhaseForminsGlutamineHumansKeratin-18MaleMiceNeoplasm ProteinsOrganelle SizeAdaptor Proteins, Signal TransducingBiomarkers, TumorDIAPH3 protein, humanForminsGlutamineKeratin-18KRT18 protein, humanNeoplasm Proteinsamoeboid blebbingcancer metabolismextracellular vesiclesSILAC Proteomicstumor progression

Identifiers

PMID25857301
PMCPMC4484459
OpenAlexW1959468401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.